Cohen & Steers(CNS)
Search documents
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
Businesswire· 2026-03-27 11:29
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001 Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001 Share The Planned Multicenter Phase 1 Trial Will Evaluate STAR-001 as Monotherapy and in Combination with Spironolactone in Children with Relapsed or Refractory CNS Malignancies, Including ATRT, DIPG, GBM, Medulloblastoma, and Ependymoma DALLAS-- ...
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications
Prnewswire· 2026-03-26 12:50
<!doctype html> <!-- For structured data --> <!-- For language declaration --> Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationSACRAMENTO, Calif., March 26, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced it has executed a binding $20 million strategic transaction to acquire blo ...
Cohen & Steers Closed-End Funds Declare Distributions for April, May and June 2026
Prnewswire· 2026-03-24 21:06
Cohen & Steers Closed-End Funds Declare Distributions for April, May and June 2026 Accessibility StatementSkip NavigationNEW YORK, March 24, 2026 /PRNewswire/ -- The Board of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for April, May and June 2026, as summarized in the charts below:TickerFund NameMonthlyDividendFOFCohen & Steers Closed-End Opportunity Fund, Inc.$0.087LDPCohen & Steers Limited Duration Preferred and Income Fund, Inc.$0.131PSFCohen & Steers Selec ...
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
Businesswire· 2026-03-13 12:03
Core Viewpoint - Alto Neuroscience is actively participating in various investor conferences and has announced the completion of patient enrollment in a Phase 2 clinical trial for its drug candidate ALTO-101, aimed at treating cognitive impairment associated with schizophrenia [1][1][1] Group 1: Company Announcements - Alto Neuroscience will participate in the Stifel 2026 Virtual CNS Forum on March 17, 2026, with a live webcast available for investors [1] - The company is also set to participate in the TD Cowen 46th Annual Healthcare Conference from March 2-5, 2026, with a presentation scheduled for March 3, 2026, at 1:50 PM ET [1] Group 2: Clinical Development - Alto Neuroscience has completed patient enrollment in its Phase 2 proof-of-concept clinical trial for ALTO-101, a transdermal phosphodiesterase-4 (PDE4) inhibitor targeting cognitive impairment associated with schizophrenia [1] Group 3: Research Contributions - A review co-authored by Alto Neuroscience's leadership team has been published in the American Journal of Psychiatry, discussing neuroplasticity as a core driver of psychiatric diseases and potential treatments [1]
LG CNS and Palantir Announce Strategic Partnership to Accelerate AI Transformation
Businesswire· 2026-03-11 23:00
Group 1 - LG CNS and Palantir Technologies have announced a strategic partnership to accelerate AI Transformation (AX) initiatives across the LG Group, aiming to drive enterprise-wide AX [1] - The partnership builds on a previous deployment of Palantir software within an LG affiliate, which has shown significant improvements in quality management and is set to expand across the entire LG Group [1] - A dedicated Forward Deployed Engineering (FDE) team will be formed to work with LG CNS and its affiliates to identify and execute high-value AX use cases across various industries, including advanced manufacturing, energy, electronics, and logistics [1] Group 2 - Ryan Taylor, Chief Revenue Officer of Palantir, emphasized that the partnership with LG Group represents a significant opportunity to leverage technology for transformational business impact [1] - Shin-gyoon Hyun, CEO of LG CNS, stated that this partnership marks a pivotal turning point in expanding LG CNS's AX business globally, combining industry expertise with Palantir's AI capabilities [1] - LG CNS is recognized as a leading Korean AX company, pioneering technologies such as AI, robotics, and cloud computing, and is focused on driving innovation across various sectors [1]
JHG vs. CNS: Which Stock Is the Better Value Option?
ZACKS· 2026-03-11 16:42
Core Viewpoint - The comparison between Janus Henderson Group plc (JHG) and Cohen & Steers Inc (CNS) indicates that JHG currently offers better value for investors based on various financial metrics and rankings [1][3]. Valuation Metrics - JHG has a forward P/E ratio of 11.29, significantly lower than CNS's forward P/E of 19.16, suggesting that JHG is undervalued relative to CNS [5]. - The PEG ratio for JHG is 1.45, while CNS has a PEG ratio of 1.88, indicating that JHG's expected earnings growth is more favorable compared to its price [5]. - JHG's P/B ratio stands at 1.49, compared to CNS's P/B of 5.28, further highlighting JHG's relative undervaluation [6]. Earnings Outlook - JHG holds a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while CNS has a Zacks Rank of 4 (Sell), suggesting a less favorable earnings outlook [3][6]. - The solid earnings outlook for JHG, combined with its favorable valuation metrics, positions it as the superior value option compared to CNS [6].
Cohen & Steers Announces Plan to Convert the Cohen & Steers Future of Energy Fund to ETF
Prnewswire· 2026-03-11 13:12
Core Viewpoint - Cohen & Steers, Inc. plans to convert the Cohen & Steers Future of Energy Fund into an actively managed ETF, aiming to enhance trading flexibility, portfolio transparency, and tax efficiency for shareholders [1]. Group 1: Fund Conversion Details - The conversion of the Cohen & Steers Future of Energy Fund to an ETF has been approved by the Fund's Board of Directors and is expected to be completed in June 2026 [1]. - The ETF will be managed by the same portfolio management team and will pursue the same investment objectives as the current mutual fund [1]. Group 2: Benefits of Conversion - The conversion is intended to provide shareholders with enhanced trading flexibility, increased transparency of portfolio holdings, and improved tax efficiency [1]. Group 3: Existing ETFs - Upon completion of the conversion, the Cohen & Steers Future of Energy Fund will become the firm's sixth actively managed ETF, joining five other ETFs: CSSD, CSPF, CSNR, CSIO, and CSRE [1]. Group 4: Company Overview - Cohen & Steers, Inc. is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, and commodities [1]. - The firm was founded in 1986 and is headquartered in New York City, with additional offices in London, Dublin, Hong Kong, Tokyo, and Singapore [1].
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
Accessnewswire· 2026-03-11 12:35
Core Insights - CNS Pharmaceuticals has launched a new corporate strategy aimed at building a high-value pipeline in neurology and oncology, two rapidly growing sectors in biopharma [1] - The newly formed executive team is focused on acquiring differentiated therapeutic assets and leveraging their extensive experience in drug development [1] - A comprehensive strategic review was conducted to evaluate the existing pipeline and market opportunities, incorporating various analytical models [1] Company Strategy - The company is pivoting from a singular focus on glioblastoma to a broader strategy that includes acquiring or in-licensing preclinical and clinical-stage assets in neurology and oncology [1] - CNS Pharmaceuticals aims to prioritize programs with strong biological rationale, differentiated mechanisms of action, and compelling clinical and commercial potential [1] - The company plans to explore out-licensing of legacy assets TPI 287 and berubicin to concentrate resources on new acquisitions [1] Market Context - Neurology and oncology are identified as two of the most active and rapidly advancing sectors in biotechnology, supported by large global markets and significant scientific innovation [1] - The strategic transformation is seen as a common and successful approach in biotechnology, with the potential to create substantial value [1] - The company is committed to advancing novel treatments that address significant unmet medical needs while creating long-term value for patients and shareholders [1]
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
Prnewswire· 2026-03-10 20:01
Core Insights - Neurocrine Biosciences, Inc. will participate in the Stifel 2026 Virtual CNS Forum on March 17, 2026, at 4:30 PM EST, with a live webcast available on their website [1] Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on developing treatments for neurological, psychiatric, endocrine, and immunological disorders [1] - The company has a diverse portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, with some treatments developed in collaboration with AbbVie [1] - Neurocrine has a robust pipeline with multiple compounds in mid- to late-phase clinical development across its core therapeutic areas [1] - The company has been applying insights into neuroscience for three decades to address complex conditions and aims to relieve suffering for patients with significant needs [1]
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Globenewswire· 2026-03-10 20:00
Company Overview - Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment [3] - The company is headquartered in Newton, Massachusetts [3] Product Development - Acumen is advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody, currently in a Phase 2 clinical trial (ALTITUDE-AD) for early symptomatic Alzheimer's disease patients [3] - The company reported positive results from its Phase 1 trial (INTERCEPT-AD) [3] - Acumen is also exploring a subcutaneous formulation of sabirnetug using Halozyme's ENHANZE® drug delivery technology [3] - Additionally, Acumen is collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer's disease utilizing a transferrin-receptor-targeting technology [3] Upcoming Events - Management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 18, 2026, at 11:00 a.m. ET [1] - The live webcast will be accessible under the Investors tab on the company's website and archived for 90 days [2]
